Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13051MR)

This product GTTS-WQ13051MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13051MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8614MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ10918MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ11465MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ11307MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ3671MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ13066MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ10631MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ14765MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-35
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW